Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial

BACKGROUND: Few trials have compared homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines. The aim of this study was to assess immune responses, safety, and efficacy against SARS-CoV-2 infection following homologous or heterologous third-dose CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Nancy H L, Cheng, Samuel M S, Cohen, Carolyn A, Martín-Sánchez, Mario, Au, Niki Y M, Luk, Leo L H, Tsang, Leo C H, Kwan, Kelvin K H, Chaothai, Sara, Fung, Lison W C, Cheung, Alan W L, Chan, Karl C K, Li, John K C, Ng, Yvonne Y, Kaewpreedee, Prathanporn, Jia, Janice Z, Ip, Dennis K M, Poon, Leo L M, Leung, Gabriel M, Peiris, J S Malik, Valkenburg, Sophie A, Cowling, Benjamin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528748/
https://www.ncbi.nlm.nih.gov/pubmed/37549680
http://dx.doi.org/10.1016/S2666-5247(23)00216-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528748/
https://www.ncbi.nlm.nih.gov/pubmed/37549680
http://dx.doi.org/10.1016/S2666-5247(23)00216-1

Ejemplares similares